



## **Mycovia Pharmaceuticals to Participate in On-Demand Women's Health Panel at BIO Digital 2020**

*CEO Patrick Jordan and biopharmaceutical executives to discuss prioritizing women's health to the forefront at the global virtual gathering of biotech industry companies*

Durham, N.C. – June 8, 2020 – [Mycovia Pharmaceuticals, Inc.](#) ("Mycovia") today announced that Chief Executive Officer Patrick Jordan will join the panel session "Redefining BioPharma in a Female-Forward World" to discuss the importance of women's health at BIO Digital. BIO Digital will be held virtually from June 8-12 due to the COVID-19 pandemic. Mycovia's oteseconazole (VT-1161), an oral antifungal product candidate for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), is currently in Phase 3 clinical development. RVVC is a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year and for which there is currently no FDA-approved treatment in the U.S.

The panel will explore how women's health has been an underserved area within biopharma research and development, the significant market opportunity in women's health and the groundbreaking work of companies that are leading the field's transformation.

"I am excited to join this panel of biopharma industry executives and thought leaders who bring such important voices to the women's health conversation," said Mr. Jordan. "Through industry events like BIO Digital, we will continue to drive partnerships and innovation that can address the significant unmet health needs, like RVVC, for women worldwide."

The latest UN estimates show men slightly outnumber women globally, but the future of biopharma is female. As life expectancies increase, women clearly outnumber men at older ages (e.g., 55% of those aged 65 years globally), which means society is facing unprecedented healthcare challenges.

Hundreds of millions of women experience diseases that are in need of new therapies and improved access, from treatments for conditions affecting reproductive health to migraines, including social and cultural needs over a lifetime. This translates to a market opportunity, as a recent BCC Research report found these challenges are driving the women's health market.

The on-demand panel session will be available on BIO Digital's website from June 8, 2020 through July 11, 2020.

### **About Mycovia Pharmaceuticals**

Mycovia Pharmaceuticals has a passion for developing breakthrough therapies in areas of unmet medical need, with an initial focus in women's health. Our lead product candidate, oteseconazole (VT-1161), is a novel, oral therapy for RVVC, that is designed with the goal of having greater selectivity, fewer side effects and improved efficacy. While not yet approved by the FDA, oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations to support its potential to be the first FDA-approved treatment for RVVC. Oteseconazole is currently in Phase 3 clinical trials designed to

establish its safety and efficacy in RVVC patients. In 2019, Mycovia licensed oteseconazole to Jiangsu Hengrui Medicine Co., to develop and commercialize oteseconazole in China, including mainland China, Hong Kong, Macau and Taiwan, and Gedeon Richter Plc., a Hungary-based pharmaceutical company, to commercialize and manufacture oteseconazole in Europe, Russia, the Commonwealth of Independent States, Latin America and Australia. Mycovia also recognizes a tremendous potential for its oral fungal inhibitors and a growing need to treat a range of multi-drug resistant fungal pathogens. For more information, please visit [www.mycovia.com](http://www.mycovia.com).

#### **About Recurrent Vulvovaginal Candidiasis**

RVVC is a debilitating, chronic infectious condition that affects millions of women. Primary symptoms include vaginal itching, burning, irritation and inflammation. Some women may experience abnormal vaginal discharge and painful sexual intercourse or urination, causing variable but often severe discomfort and pain. RVVC impacts quality of life, to a degree comparable to asthma and worse than diseases such as headache and migraine.

#### **Contacts**

Mycovia Pharmaceuticals, Inc.  
Tiffany Ahlers, 919-467-8539  
[tahlers@mycovia.com](mailto:tahlers@mycovia.com)

#### **Media**

FleishmanHillard  
Anuj Baveja, 919-334-3782  
[anuj.baveja@fleishman.com](mailto:anuj.baveja@fleishman.com)

###